Ver­tex and CRISPR send exa-cel for FDA ap­proval; Aridis Ther­a­peu­tics ax­es 20% of its work­force

Ver­tex and CRISPR Ther­a­peu­tics have fin­ished the BLA for its treat­ment ex­agam­glo­gene au­totem­cel, or exa-cel, and will be go­ing to­ward the FDA for ap­proval. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER